Navigation Links
GeoVax Labs Reports Fourth Quarter and Year-End 2010 Financial Results
Date:2/25/2011

, antiretroviral treatment in low and middle income countries was restricted to about 3 million people. In the United States, about 50% of those who are infected are estimated to be on drug treatment.

Forward-Looking StatementsCertain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act.  These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether:  HVTN will commence, complete enrollment, and generate data regarding GeoVax vaccine clinical trials as and when expected, GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective, less costly, or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.

FINANCIAL TABLES FOLLOWGEOVAX LABS, INC.Statements of Operations Data(amounts in thousands, except per share data)Three Months Ended

Year EndedDecember 31,

December 31, 2010

2009

2010

2009Grant Revenue$  946

$  397

$  5,185

$  3,668
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
2. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
3. GeoVax Presents Data at AIDS Vaccine 2008 Conference
4. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
5. GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
6. GeoVax to Present at the BIO CEO & Investor Conference 2009
7. GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference
8. GeoVax Update Provided at the BIO CEO & Investor Conference 2009
9. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results
10. GeoVax Labs, Inc. Announces First Quarter Financial Results
11. GeoVax to Exhibit at the 2009 BIO International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... new research platform uses a laser to ... undergoing stress and heating, an approach likely ... microelectronics and batteries., This new technique, called ... heating and the surface stress of microscale ... discussed the merits of surface-stress influence on ...
(Date:8/28/2014)... 2014  Next month, executives from clinical trial marketing firm ... beginning with Patient-Centered Clinical Trials 2014 , to be ... , September 4-5. Patient recruitment experts Bonnie A. ... will share insights on the benefits of employing an ... – from media to mobile apps – can be used ...
(Date:8/28/2014)... by a Florida State University research team has led ... temperature, emit white light, and convert photon energy directly ... a butterfly. , Biwu Ma, associate professor in the ... College of Engineering, created the molecule in a lab ... that his creation has many other unique capabilities. , ...
(Date:8/28/2014)... PrimeSource Building Products, Inc., a leading ... to support their communication needs with the ... conferencing platform GlobalMeet powered by SoundConnect. The solution ... SoundConnect delivers award winning “results driven” business class ... be utilizing GlobalMeet powered by SoundConnect ...
Breaking Biology Technology:New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3BBK Worldwide Leads Sessions at Key September Events 2Novel 'butterfly' molecule could build new sensors, photoenergy conversion devices 2PrimeSource Chooses SoundConnect as Collaboration Provider 2
... tiny components on silicon wafers) has long enabled the ... number of transistors that can be squeezed into an ... compensating capabilities of plasma etching, Moore,s Law would have ... micron (the diameter of a human hair is approximately ...
... 2011 Bayer HealthCare,s affiliate MEDRAD, Inc. today ... demonstrated a 59 percent relative reduction in target ... patients with peripheral arterial disease (PAD) treated with ... compared to standard balloon angioplasty (POBA). Additionally, for ...
... /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. ... outsourcing company serving the pharmaceutical, biotechnology, and medical device industries, ... its financial results for the third quarter of 2011. ... Increased 24.0% Year Over Year to $104.0 Million ...
Cached Biology Technology:Plasma etching pushes the limits of a shrinking world 2Bayer HealthCare's Cotavance® Drug Eluting Balloon With Paccocath® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon 2Bayer HealthCare's Cotavance® Drug Eluting Balloon With Paccocath® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon 3Bayer HealthCare's Cotavance® Drug Eluting Balloon With Paccocath® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon 4WuXi PharmaTech Announces Third-Quarter 2011 Results 2WuXi PharmaTech Announces Third-Quarter 2011 Results 3WuXi PharmaTech Announces Third-Quarter 2011 Results 4WuXi PharmaTech Announces Third-Quarter 2011 Results 5WuXi PharmaTech Announces Third-Quarter 2011 Results 6WuXi PharmaTech Announces Third-Quarter 2011 Results 7WuXi PharmaTech Announces Third-Quarter 2011 Results 8WuXi PharmaTech Announces Third-Quarter 2011 Results 9WuXi PharmaTech Announces Third-Quarter 2011 Results 10WuXi PharmaTech Announces Third-Quarter 2011 Results 11WuXi PharmaTech Announces Third-Quarter 2011 Results 12WuXi PharmaTech Announces Third-Quarter 2011 Results 13WuXi PharmaTech Announces Third-Quarter 2011 Results 14WuXi PharmaTech Announces Third-Quarter 2011 Results 15WuXi PharmaTech Announces Third-Quarter 2011 Results 16WuXi PharmaTech Announces Third-Quarter 2011 Results 17WuXi PharmaTech Announces Third-Quarter 2011 Results 18
(Date:8/29/2014)... connections in transcription factor networks (TFNs) to evaluate the ... in PLOS Computational Biology in August. ... a network,s resilience against mutations. , "In simulations, ... models has a greater effect on robustness than varying ... Dov A. Pechenick, PhD, lead author and former researcher ...
(Date:8/29/2014)... twist them, fold them: modern materials that are light, ... as artificial skin or electronic paper. , Making such ... but a new way of working with copper nanowires ... , Previous success in the field of ultra-lightweight ... precious gold and silver nanowires. , By turning ...
(Date:8/28/2014)... study reports that an expansion of marine protected areas ... ecological functions. According to investigators from the Wildlife ... fish have focused on saving the largest numbers of ... provide key and difficult-to-replace ecological functions. , ... by fish species that also are food for millions ...
Breaking Biology News(10 mins):Assortativity signatures of transcription factor networks contribute to robustness 2Copper shines as flexible conductor 2Study finds marine protected areas inadequate for protecting fish and ocean ecology 2
... Infectious Diseases (NIAID), part of the National Institutes of ... to Tulane University for its ongoing efforts to treat ... that threatens hundreds of thousands of people annually in ... threat. The contract will include collaboration between Tulane; ...
... are going on a diet, while others have expanding ... rising temperatures due to global climate change, speculates Prof. ... who has been measuring the evolving body sizes of ... most extreme. , Changes are happening primarily in higher ...
... (February 5, 2010) New research from the Hood Center for ... first time sheds light on the significant potential negative impact ... on children. The study, which appears in the current ... of the "brand placements" for food, beverage, and food retail ...
Cached Biology News:Tulane receives $15 million NIH contract to develop vaccine and treatment for deadly fever 2Animals cope with climate change at the dinner table 2New study examines the impact on children of food product placements in the movies 2New study examines the impact on children of food product placements in the movies 3
Each 72-well MiniTray is low profile, with lid. Conical well shape, 10 l....
The E. coli Expression System with Gateway Technology is designed to create E. coli expression clones containing the T7 promoter. The expression clones are ready for transformation and expression in ...
...
For use with SSP products or any application requiring agarose gel separation • Multiple formats available to meet various throughput needs • Includes replacement parts for each un...
Biology Products: